ClinicalTrials.gg

Program

duvakitug

Also written as “Duvakitug”, “TEV-48574” and “TEV-48574 Dose Regimen A”.

In Sanofi's pipeline, TL1A mAb. Its studies are mostly in Crohn Disease · Colitis, Ulcerative · Hidradenitis · Asthma, led by 2 companies.

Furthest: phase 3, since Sep 15, 20259 company-led studies, 7 open or runningNext primary completion: May 9, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi66 open or runningphase 3since Sep 15, 2025Sep 15, 2025May 9, 2028phase 3 · NCT07184996
Teva Pharmaceutical Industries31 open or runningphase 2since Aug 24, 2020Aug 24, 2020none ahead
  • Named in Sanofi’s own pipeline as duvakitug, phase 3, as of Sep 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 24, 2020First study: phase 2 study in AsthmaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT04545385 · 65 enrolled · United States, Bulgaria, Czechia and more
  2. Aug 11, 2022Phase 2 study in Crohn DiseaseTeva Pharmaceutical Industries · NCT05499130 · 290 enrolled · United States, Austria, Belgium and more
  3. Dec 12, 2022Phase 2 study in Crohn DiseaseTeva Pharmaceutical Industries · NCT05668013 · 247 enrolled · United States, Austria, Bulgaria and more
  4. Sep 15, 2025Sanofi's first studies: 4 phase 3 studiesNew to SanofiSanofi · NCT07185009, NCT07184996, NCT07184944 and 1 more
  5. Sep 4, 2026Phase 2 study in HidradenitisSanofi · NCT07812116 · 156 planned · United States, Canada
  6. Nov 2, 2026Phase 1 study in Colitis, UlcerativeSanofi · NCT07923383 · 25 planned

Ahead

  1. May 9, 2028Primary completion: phase 3 study in Colitis, UlcerativeSanofi · NCT07184996
  2. Jun 16, 2028Primary completion: phase 2 study in HidradenitisSanofi · NCT07812116
  3. Aug 8, 2028Primary completion: phase 1 study in Colitis, UlcerativeSanofi · NCT07923383
  4. Sep 21, 2028Primary completion: phase 3 study in Colitis, UlcerativeSanofi · NCT07185009

TargetBeta

“TL1A mAb”the company's pipeline, read by Claude · source

Other programs on TNFSF15

ProgramCompanyFurthest phaseStudies
PF-07261271Pfizerphase 11

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07923383Colitis, Ulcerative1Not yet recruitingSanofiAug 8, 202825
NCT07812116Hidradenitis · United States, Canada2RecruitingSanofiJun 16, 2028156
NCT07185009Colitis, Ulcerative · United States, Argentina, Australia and more3RecruitingSanofiSep 21, 2028751
NCT07184996Colitis, Ulcerative · United States, Argentina, Australia and more3RecruitingSanofiMay 9, 2028980
NCT07184944Crohn Disease · United States, Australia, Austria and more3RecruitingSanofiAug 13, 2029751
NCT07184931Crohn Disease · United States, Argentina, Australia and more3RecruitingSanofiMay 14, 2029980
NCT05668013Crohn Disease · United States, Austria, Bulgaria and more2Active, not recruitingTeva Pharmaceutical IndustriesJan 5, 2026247
NCT05499130Crohn Disease · United States, Austria, Belgium and more2CompletedTeva Pharmaceutical IndustriesNov 12, 2024290
NCT04545385Asthma · United States, Bulgaria, Czechia and more2TerminatedTeva Pharmaceutical IndustriesJan 17, 202265

How it is read

Names in the registry

  • “Duvakitug”, 6 entries
  • “TEV-48574”, 2 entries
  • “TEV-48574 Dose Regimen A”, 1 entry
  • “TEV-48574 Dose Regiment B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.